The Science Behind Lantern Pharma

Publications and Posters

Lantern Pharma’s innovations, oncology drug-development processes and results from our research are reflected in numerous publications and posters. Sharing our results with the broader clinical and scientific community has the potential to improve our research, develop additional insights and foster new collaborations that can help us discover methods and insights that can conquer cancer.

Lantern Pharma Publications

View and display our publications.

The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

Kulkarni A., McDermott J. R., Kathad U., Modali R., Richard J. P., Sharma P., Bhatia K.

April 13, 2021
Learn More
Learn More

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

Umesh Kathad, Aditya Kulkarni, Joseph Ryan McDermott, Jordan Wegner, Peter Carr, Neha Biyani, Rama Modali, Jean‐Philippe Richard, Panna Sharma and Kishor Bhatia

March 2, 2021
Learn More
Learn More

A machine learning‑based gene signature of response to the novel alkylating agent LP‑184 distinguishes its potential tumor indications

Kathad U., Kulkarni A., McDermott J. R., Wegner J., Carr P., Biyani N., Modali R., Richard J. P., Sharma P., Bhatia K.

March 2, 2021
Learn More
Learn More

Hydroxyurea derivatives of irofulven with improved antitumor efficacy

Staake M.D., Kashinatham A., McMorris T.C., Estes L.A., Kelner M.J.

April 1, 2016
Learn More
Learn More

Cysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787

Parker A.R., Petluru P.N., Nienaber V.L., Badger J., Leverett B.D., Jair K., Sridhar V., Logan C., Ayala P.Y., Kochat H., Hausheer F.H.

March 18, 2015
Learn More
Learn More

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

Parker A.R., Petluru P.N., Nienaber V.L., Zhao M., Ayala P.Y., Badger J., Chie-Leon B., Sridhar V., Logan C., Kochat H., Hausheer F.H.

February 4, 2015
Learn More
Learn More

Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor

Van Midwoud P.M., Sturla S.J.

November 18, 2013
Learn More
Learn More

Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent

Yu X., Erzinger M.M., Pietsch K.E., Cervoni-Curet F.N., Whang J., Niederhuber J., Sturla S.J.

November 1, 2012
Learn More
Learn More

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

Masuda N., Negoro S., Hausheer F., Nakagawa K., Matsui K., Kudoh S., Takeda K., Yamamoto N., Yoshimura N., Ohashi Y., Fukuoka M.

May 15, 2010
Learn More
Learn More

Enantioselective total synthesis of (−)-Acylfulvene and (−)- Irofulven

Siegel D.S., Piizzi G., Piersanti G., Movassaghi M.

November 25, 2009
Learn More
Learn More

Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells

Escargueil A.E., Poindessous V., Soares D.G., Sarasin A., Cook P.R., Larsen A.K.

April 15, 2008
Learn More
Learn More

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule

Boven E., Westerman M., van Groeningen C.J., Verschraagen M., Ruijter R., Zegers I., van der Vijgh W.J.F., Giaccone G.

April 19, 2005
Learn More
Learn More

Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo

Van Laar E.S., Roth S., Weitman S., MacDonald J.R., Waters S.J.

January 1, 2004
Learn More
Learn More

Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent

Herzig M.C., Trevino A.V., Liang H., Salinas R., Waters S.J., MacDonald J.R., Woynarowska B.A., Woynarowski J.M.

February 15, 2003
Learn More
Learn More

Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways

Jaspers N.G., Raams A., Kelner M.J., Ng J.M., Yamashita Y.M., Takeda S., McMorris T.C., Hoeijmakers J.H.

December 5, 2002
Learn More
Learn More

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

Kelner M.J., McMorris T.C., Estes L., Samson K.M., Bagnell R.D., Taetle R.

May 1, 1998
Learn More
Learn More

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

Kelner M.J., McMorris T.C., Estes L., Wang W., Samson K.M., Taetle R.

June 1, 1996
Learn More
Learn More

Efficacy of acylfulvene illudili analogues against a metastatic lung carcinoma MV 522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC 2

Efficacy of acylfulvene illudili analogues against a metastatic lung carcinoma MV 522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC 2 and ERCC 3 DNA helicase-deficient cells

Kelner M.J., Mcmorris T.C., Estes L.A., Starr R.J., Rutherford M., Montoya M., Samson K.M., Taetle R.

November 1, 1995
Learn More
Learn More

Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents

Kelner M.J., McMorris T.C., Estes L., Rutherford M., Montoya M., Goldstein J., Samson K., Starr R., Taetle R.

July 19, 1994
Learn More
Learn More

Lantern Pharma Posters

View and display the results of our oncology drug testing, with in-depth statistics and conclusions regarding efficacy and potential for further development and advances in treatment.

Download Lantern's AACR 2020 Poster 1

Download Now

Download Lantern's AACR 2020 Poster 2

Download Now

Download Lantern's AACR 2021 Poster

Download Now

Download Lantern's ASCO 2019 Poster

Download Now

Download Lantern's AACR 2019 Poster 1

Download Now

Download Lantern's AACR 2019 Poster 2

Download Now

Download Lantern's AACR 2019 Poster 3

Download Now
"We are in the golden age of A.I. where we are able to significantly impact the speed and precision at which we develop new drugs."
Panna Sharma
PRESIDENT & CEO, LANTERN PHARMA